Friday 6 November 2026 Export TELO’s income statement to Excel — free account

Telomir Pharmaceuticals, Inc.

TELO Healthcare Biotechnology

EPS: −364.7%
Free cash flow: −45.3%

Quarter to June 2026, against a year earlier

0.73 0.05 −6.41%

Follow TELO

Alert me

Market cap: $57.5M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
ROE Full definition →	+8 more TTM periods Free account	(301.57%)	(317.65%)	(384.26%)	(1,885.50%)
ROA Full definition →		(265.05%)	(240.34%)	(293.73%)	(1,678.31%)
ROIC Full definition →		0.00%	0.00%	0.00%	0.00%
Return on Tangible Assets Full definition →		(160.34%)	(176.09%)	(185.89%)	(1,032.88%)
Free Cash Flow per Share Full definition →		(0.10)	(0.12)	(0.13)	(0.08)
Free Cash Flow Full definition →		(3.09)	(3.69)	(4.60)	(4.91)
Other line items
Cash ROIC Full definition →		(21.61%)	(27.94%)	(42.87%)	(47.53%)
Accounts Payable Turnover Full definition →		0.00	0.00	0.00	0.00
Average Days of Payables Full definition →		0.00	0.00	0.00	0.00
Tax Rate Full definition →		0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Share Based Compensation of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Interest Coverage Full definition →		—	—	(3,612.46)	(1,087.00)
Operating CF/Net income Full definition →		0.28	0.35	0.50	0.09
Revenue per Share Full definition →		0.00	0.00	0.00	0.00
Operating CF per Share Full definition →		(0.10)	(0.12)	(0.13)	(0.08)
Capex per Share Full definition →		0.00	0.00	0.00	0.00

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026